Othman Al-Sawaf, MD, University Hospital of Cologne, Cologne, Germany, shares the six-year updated results of the CLL14 trial (NCT02242942) which compared fixed-duration venetoclax plus obinutuzumab (VenG) to chlorambucil plus obinutuzumab (ClbG) for patients with previously untreated chronic lymphocytic leukemia (CLL). Dr Al-Sawaf shares the positive long-term efficacy and safety results of fixed-duration VenG compared to chemoimmunotherapy. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
